89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors.

Trial Profile

89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neuroendocrine tumours
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top